IgY for Inhibition of Pathological Modified Peptides in Celiac Disease

</a><strong>Background</strong><br>

Celiac disease is a worldwide autoimmune disorder characterized by gluten intolerance, and is associated with a number of serious clinical conditions. Even though the prevalence of celiac disease is about 1%, there is still no special therapy; therefore people with celiac disease have to follow a strict gluten-free diet.<br><br> <strong>Technology</strong><br> We offer a novel polyclonal IgY antibody for the treatment of Celiac Disease. The treatment is based on the application of polyclonal anti-CD3 or anti-CDPtTG antibodies, which recognize a specific pathogen peptide. The antibodies are able to bind CD3-peptides and to inhibit human autoantibodies against tTG, without activating the immune system. <br><br> The antibodies are produced in high quantities in the egg yolk of chicken through specific immunization. <br><br> <b>Benefits:</b><ul> <li>Polyclonal chicken antibodies expressed in yolk (no purification necessary)</li> <li>Inhibition of all tested patient autoantibodies against CDP and tTG (75 pts.)</li> <li>Inhibition of tTG enzymatic activity</li> <li>No interaction with non-pathogenic unmodified gluten </li></ul> <p><strong>IP Rights</strong><br> German patent application filed 09/2011 <br><br> <strong>Patent Owner</strong><br> Charité – Universitätsmedizin Berlin

Weitere Informationen: PDF

ipal GmbH
Tel.: +49 (0)30/2125-4820

Ansprechpartner
Dr. Dirk Dantz